Thyroid stunning in clinical practice: is it a real problem?
Stunning is a phenomenon of reducing (131)I uptaking activity by residual or metastatic tissue during the follow-up of patients after total thyroidectomy for differentiated thyroid carcinoma. It was observed at whole body scintigraphy performed after therapeutic dose, administered for remnant ablation, in patients who were previously given a (131)I dose for diagnostic purpose. This phenomenon could influence the efficacy of radioisotopic therapy, making it unsuccessful. Stunning was observed also in case of hyperthyroidism treated by fractionated doses of (131)I. After a careful revision of literature, Authors report their last 10 years-experience about very few cases of supposed stunning, observed in oncological and hyperthyroidal patients who underwent diagnostic scan and radioiodine therapy. In case of differentiated thyroid carcinoma, we recommended a careful selection of patients who will be given ablative therapy using very low diagnostic doses and administering further therapeutic dose in a short time. In case of hyperthyroidism treatment, it is confirmed the opportunity of a single therapeutic dose with TSH value within the normal range. Because it was found out a very small number of cases in our wide population, we conclude that stunning is not influent in clinical practice, above all if ''well-practice'' diagnostic-therapeutical procedures are strictly observed.
Filesi
M
M
Department of Clinical Sciences and Nuclear Medicine Policlinico Umberto I La Sapienza University Rome, Italy.
Colandrea
M
M
Montesano
T
T
D'Apollo
R
R
Ronga
G
G
D018263:Adenocarcinoma, Follicular / Q000378:metabolism / Q000532:radiotherapy; D002291:Carcinoma, Papillary / Q000378:metabolism / Q000532:radiotherapy; D006801:Humans; D006980:Hyperthyroidism / Q000378:metabolism / Q000532:radiotherapy; D007455:Iodine / Q000378:metabolism; D007457:Iodine Radioisotopes / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D019275:Radiopharmaceuticals / Q000009:adverse effects / Q000627:therapeutic use; D011879:Radiotherapy Dosage; D013961:Thyroid Gland / Q000378:metabolism* / Q000503:physiopathology / Q000528:radiation effects; D013964:Thyroid Neoplasms / Q000378:metabolism / Q000532:radiotherapy
D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals; D007455:Iodine